Franklin Biotechnology Financial Statements From 2010 to 2024
| FBTDX Fund | USD 118.31 1.01 0.86% |
Check Franklin Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Franklin main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Franklin financial statements analysis is a perfect complement when working with Franklin Biotechnology Valuation or Volatility modules.
Franklin |
Franklin Biotechnology Discovery Mutual Fund Price To Sales Analysis
Franklin Biotechnology's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Franklin Biotechnology Price To Sales | 6.21 X |
Most of Franklin Biotechnology's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Franklin Biotechnology Discovery is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Franklin Biotechnology Discovery has a Price To Sales of 6.21 times. This is much higher than that of the Franklin Templeton Investments family and significantly higher than that of the Health category. The price to sales for all United States funds is notably lower than that of the firm.
Franklin Biotechnology Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Franklin Biotechnology's current stock value. Our valuation model uses many indicators to compare Franklin Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Franklin Biotechnology competition to find correlations between indicators driving Franklin Biotechnology's intrinsic value. More Info.Franklin Biotechnology Discovery is one of the top funds in price to earning among similar funds. It is one of the top funds in price to book among similar funds fabricating about 0.23 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for Franklin Biotechnology Discovery is roughly 4.37 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Franklin Biotechnology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Franklin Biotechnology's Mutual Fund. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Franklin Biotechnology's earnings, one of the primary drivers of an investment's value.About Franklin Biotechnology Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Franklin Biotechnology income statement, its balance sheet, and the statement of cash flows. Franklin Biotechnology investors use historical funamental indicators, such as Franklin Biotechnology's revenue or net income, to determine how well the company is positioned to perform in the future. Although Franklin Biotechnology investors may use each financial statement separately, they are all related. The changes in Franklin Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Franklin Biotechnology's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Franklin Biotechnology Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Franklin Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
Under normal market conditions, the fund invests at least 80 percent of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies, the fund may also invest up to 20 percent of its net assets in equity or debt securities of any type of issuer. It is non-diversified.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Franklin Biotechnology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Franklin Biotechnology's short interest history, or implied volatility extrapolated from Franklin Biotechnology options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Franklin Biotechnology Correlation against competitors. Note that the Franklin Biotechnology information on this page should be used as a complementary analysis to other Franklin Biotechnology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.